Articles with keyword PD-L1

• Neoadjuvant anti PD-1 / PD-L1 immune checkpoint inhibitors in locall y advanced gastric cancer with microsatellite insta bility

  A.Y. Navmatulya, V.A. Chubenko, S.A. Savchuk, F.R. Almukhametova, P.Y. Tsuprun, A.I. Kuznetsov, G.S. Inusilaev, V.A. Heinstein, K.V. Shelekhova, Е.М. Zykov, B.I. Miroshnikov, V.M. Moiseenko

  Gastric cancer, immune checkpoint inhibitors, MSI, microsatellite instability, PD-1, PD-L1, objective response, pathologic response.

• Biomarkers predicting the effect of immunotherapy: what you need to know in practice?

  A.M. Konstantinova

  immunotherapy, CTLA-4, PD-1, PD-L1, microsatellite instability, mutation burden, tumor-infiltrating lymphocytes, biomarkers, efficacy.

• SYSTEMIC THERAPY FOR ADVANCED KIDNEY CANCER

  I.V. Timofeev

  metastatic renal cell carcinoma, systemic therapy, nivolumab, ipilimumab, avelumab, axitinib, pembrolizumab, PD-L1 expression, cytoreductive nephrectomy.

• Efficacy of immune checkpoints inhibitors in the treatment of solid tumors

  A.A. Rumyantsev, S.A. Tjulandin

  drug therapy, immunotherapy, CTLA-4, PD-1, PD-L1, check-points, programmed cell death protein, nivolumab, pembrolizumab, ipilimumab, atezolizumab, biomarkers, efficacy